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Abstract: The molecular chaperone HSP90 is involved in stabilization and function of 
multiple client proteins, many of which represent important oncogenic drivers in NSCLC. 
Utilization of HSP90 inhibitors as radiosensitizing agents is a promising approach.  
The antitumor activity of ganetespib, HSP90 inhibitor, was evaluated in human lung 
adenocarcinoma (AC) cells for its ability to potentiate the effects of IR treatment in both  
in vitro and in vivo. The cytotoxic effects of ganetespib included; G2/M cell cycle arrest, 
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inhibition of DNA repair, apoptosis induction, and promotion of senescence. All of these 
antitumor effects were both concentration- and time-dependent. Both pretreatment and  
post-radiation treatment with ganetespib at low nanomolar concentrations induced 
radiosensitization in lung AC cells in vitro. Ganetespib may impart radiosensitization 
through multiple mechanisms: such as down regulation of the PI3K/Akt pathway; 
diminished DNA repair capacity and promotion of cellular senescence. In vivo, ganetespib 
reduced growth of T2821 tumor xenografts in mice and sensitized tumors to IR.  
Tumor irradiation led to dramatic upregulation of β-catenin expression in tumor tissues,  
an effect that was mitigated in T2821 xenografts when ganetespib was combined with IR 
treatments. These data highlight the promise of combining ganetespib with IR therapies in 
the treatment of AC lung tumors. 
Keywords: HSP90 inhibitor ganetespib; lung adenocarcinoma; xenografted tumors; 
ionizing radiation; senescence; apoptosis; cell cycle; DNA repair 
 
1. Introduction 
Lung cancer is responsible for one-third of all cancer deaths. NSCLC comprises 85% of all lung 
cancer cases, with adenocarcinoma (AC) representing the major histological subtype of NSCLC [1]. 
Despite decades of research, systemic therapies fail to cure most lung cancers [2–5]. Currently, IR 
therapy is an integral component of the treatment for NSCLC [3,6,7]. However, intrinsic or acquired resistance 
is considered to be the main limiting factor for the efficacy of IR in long-term treatment of lung cancer [7,8]. 
AC sensitivity to IR depends on the oncogenic genotype which is present. Tumors bearing epidermal growth 
factor receptor (EGFR) mutations, or those expressing the echinoderm microtubule-associated protein-like 4 
gene fused to the anaplastic lymphoma kinase (EML4-ALK) gene, are largely radiosensitive. The KRAS 
mutant tumors tend to be resistant to IR [9–13]. In the clinical setting, IR therapy is routinely ordered for 
patients without determination of the dominant oncogenic mutations that are present [12]. 
Experimental data has identified the mechanisms involved in repairing the DNA damage induced by 
IR and chemotherapy in the radioresistant genotypes [14–20]. Radiosensitizing agents, inhibitors of 
DNA repair, have been under consideration as therapy for decades [21]. However, little progress has 
been made as the radiosensitizing agents tested are not tumor specific and radiosensitize both normal 
and tumorigenic tissues [19]. Efforts to improve the efficacy of IR therapies using such recent 
technologies as intensity-modulated radiation therapy (IMRT) and gamma knife (stereotactic 
radiosurgery) techniques have greatly reduced the damage to normal tissues. However, delivery of  
high-dose IR is still limited due to damage to surrounding normal tissues [22–25]. The cellular 
heterogeneity present within lung tumors also presents a challenge for NSCLC therapies [26].  
Sensitivity to IR-therapy in NSCLC has been determined by monitoring the transition of epithelial 
tissues to mesenchymal tissues (EMT) [27]. We have determined that IR- resistant residual NSCLC cells 
express a complex phenotype combining cancer stem cells (CSCs), as well as EMT markers [28]. 
Radiosensitizing therapeutics which can eliminate these IR-resistant cells could have most profound 
impact on the efficacy of NSCLC therapies. 
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The abundantly expressed molecular chaperone HSP90 plays a critical protective role in folding, 
stabilizing, and aggregation for the hundreds of known HSP90 client proteins [29,30]. The basic 
mechanisms of HSP90-induced protein folding involves conformational switches between open and 
closed conformations that requires ATP hydrolysis [31,32]. ATP competitive inhibitors of HSP90 
disrupt the chaperone cycle, resulting in the destabilization and degradation of HSP90 clients [33–37]. 
Thus, HSP90 is an attractive therapeutic target since targeted inhibition of the chaperone can impact 
such a large and diverse group of protein kinases, transcription factors, and E3 ligases. Many of these 
clients are validated oncogenic drivers of lung adenocarcinoma including mutant EGFR [38], mutant 
BRAF [39], wild-type and mutant HER2 [40,41], and the EML4-ALK translocation product [42].  
A surprising and common finding with most HSP90 inhibitors is their selectivity for certain tumor cells 
and not other cells. With few exceptions in vivo, most cancer cells are more sensitive to HSP90 inhibition 
than non-transformed cells and non-toxic doses demonstrate anti-cancer activity. In animals and humans, 
HSP90 inhibitors consistently accumulate in tumors whereas they are rapidly cleared from plasma and 
do not appear to enter most tissues [43–45]. 
Ganetespib (Synta Pharmaceuticals Corp., Lexington, MA, USA) is a new potent inhibitor of HSP90 
with favorable pharmacologic and safety characteristics over the first generation of HSP90 inhibitor 
compounds [46,47]. Ganetespib is structurally distinct, relatively hydrophobic, and considerably smaller 
in size to the prototypical ansamycin class of HSP90 inhibitors. Ganetespib readily penetrates, distributes 
and is retained throughout solid tumors in in vivo models [37,47]. Ganetespib has shown preclinical 
activity against NSCLC models, including those driven by mutant EGFR, rearranged ALK, and/or 
mutant KRAS [6,48,49], and has been shown to potentiate the effect of taxanes and PI3K/mTOR 
inhibitor BEZ235 in NSCLC models [48,49]. In clinical trials, ganetespib monotherapy has a 
manageable side effect profile, as well as promising clinical activity in heavily pretreated patients with 
advanced NSCLCs, most notably in patients with tumors harboring ALK gene rearrangements [50]. 
It is reasonable to suggest that pharmacological blockade of HSP90 might produce multifaceted 
effects on various cell signaling pathways of cancer cells, including the inhibition prosurvival oncogenic 
signals in IR- and drug resistant cancers [51,52]. Studies have shown that ganetespib had a radiosensitizing 
effect in preclinical colorectal cancer model systems [53] but has not been explored in NSCLC. Here we 
examine the radiosensitizing effects of ganetespib on human lung AC cells with differing genetic 
backgrounds, including KRAS mutant A549 cells, EGFR mutant primary T2851 cells, and primary 
T2821 cells that express wild type (wt) KRAS and EGFR. 
2. Results and Discussion 
2.1. Growth Inhibitory Effect of Ganetespib on Human Lung Adenocarcinoma Cells 
To assess the anticancer activity of ganetespib on lung cancer cells, A549, T2821 and T2851 AC cell 
lines were initially cultured in the presence of graded concentrations of ganetespib for 72 h.  
All three AC cell lines were sensitive to the antiproliferative effects of ganetespib, with the T2821 cell 
line showing the greatest sensitivity (IC50, 21.2 ± 0.9 nM), and with lower sensitivities detected in T2851 
(IC50, 43.4 ± 1.5 nM) and A549 (IC50, 49.9 ± 1.9 nM) cell lines (Figure 1A). 
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3-D tumor sphere formation is frequently used to evaluate the clonogenicity of tumor cells and to 
measure the growth of putative cancer stem cells (CSCs) under serum-free and ultra-low attachment 
conditions [54–56]. Ganetespib dramatically reduced tumor sphere formation in each of the cell lines 
(Figure 1B), with T2821 cells again showing the greatest sensitivity to treatment (IC50, ~0.9 nM/IC100, 
~4 nM) versus (IC50, ~1.4 nM/IC100, ~4 nM) for A549 cells and (IC50, ~1.2 nM/IC100, ~10 nM) for 
cell line T2851. As shown in Figure 1C, a 4 nM concentration of ganetespib was sufficient to block 
sphere formation in T2821 cells; while 10 nM was required to completely abrogate this effect in T2851 
cells (data not shown). 
 
Figure 1. Ganetespib inhibits the proliferation of human lung AC cells growing as adherent 
cultures and as tumor spheres and reduces AC cells migration. (A). Tumor cells were grown 
in the presence of ganetespib (0–1000 nM) and the cellular viability was assessed after 72 h 
using a MTT assay. (B). Images of T2821 and T2851 cells cultured in adherent condition 
(upper panel) are shown. Images of tumor spheres formed from untreated T2821 and T2851 
cells (medium panel) and cells treated with 4 nM of ganetespib (lower panel) are presented. 
(C). Ganetespib inhibits lung tumor sphere formation. Cells were grown in ultra low 
attachment plates in serum free media and grown in the presence of ganetespib (0–100 nM) 
for 7 days and then the tumor spheres were counted. Results are presented as % of control. 
(D)–(F). Ganetespib reduces the motility of lung AC cells. The migratory rates were 
determined by measuring wound width as a function of time. Data are expressed as the mean 
± SD of three–six experiments. 
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2.2. Ganetespib Inhibits Lung Adenocarcinoma Cell Migration 
High migratory capacity is a key characteristic of metastatic tumor cells [57]. The effect of ganetespib 
exposure on the migration of A549, T2821 and T2851 cell lines was measured using a scratch-wound 
assay. A549 cells demonstrated higher migratory potential than the primary T2821 and T2851 lung 
tumor cells (Figure 1D,E). Ganetespib significantly reduced AC cell migration rates, in all cell lines as 
compared to untreated cell, suggesting that ganetespib treatment robustly inhibited cell migrations. 
2.3. Ganetespib Induces Apoptosis, Growth Arrest, and Senescence in Lung Adenocarcinoma Cells 
To determine whether growth inhibition by ganetespib cells was due to induction of apoptosis, cells 
were treated with graded concentrations of ganetespib for 0, 6, 24 and 48 h and apoptosis assessed by 
Annexin-V Alexa Fluor 488/PI staining and flow cytometry. Apoptosis was not detected in cells at the 
6 h time point (data not shown), nor in cells treated with ganetespib at the lowest concentrations of  
3 nM (Figure 2A–C).  
 
Figure 2. Ganetespib induces apoptosis and modulates cell cycle progression in lung AC cells. 
(A)–(C). Tumor cells were incubated with ganetespib (0–300 nM) for 24 or 48 h and then cells 
were harvested, stained with Annexin V-Alexa488/PI and measured by flow cytometry. 
Values are the mean of three independent experiments. (D)–(F). Cells were treated with 
ganetespib (0, 30 nM) for 48 h, fixed and stained with PI and the cell cycle distribution was 
measured by flow cytometry. Data shown are the mean ± SD of three experiments. 
Higher concentrations of ganetespib (30, 300 nM) induced apoptosis, which was determined to be 
both concentration- and time-dependent. The degree of early apoptotic and late apoptotic changes and 
necrotic cell death differed between the cell lines, with T2851 cells showing the lowest effect as 
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compared to the T2821 and A549 cell lines (Figure 2).To assess potential cell cycle effects in the AC 
cells, cells were treated with 30 nM ganetespib, for 48 h (Figure 2D,E). Cell cycle analysis revealed G2 
accumulation, which was associated with a concomitant loss of S phase and decreased G1 fraction, in 
each of the three cell lines. 
These data suggested that cycle arrest may lead to activation of autophagy or senescence in 
ganetespib-treated cells. To examine this possibility, we next examined two markers of autophagy: 
Expression of light chain 3 (LC3) [58] and distribution of high mobility group 1 (HMGB1)  
protein [59]. Cells were cultured in increasing concentrations of ganetespib for 48 h (Figure 3) and both 
LC3 and HMGB1 proteins were found to be significantly up-regulated in cells treated with high dose 
ganetespib (300 nM) (Figure 3A,B). Nuclear localization of HMGB1 protein was suggestive of an 
apoptotic response rather than a macro autophagy event. 
Since these effects were absent in cells treated with low concentrations of ganetespib, we next 
examined the role of cellular senescence in growth inhibitory phenotype induction by ganetespib 
treatment. To do this, multiple morphological and molecular markers of senescence were evaluated, 
including nuclear size change, the formation of senescence-associated foci (SAHF) [60], and expression 
of the cyclin-dependent kinase (CDK) inhibitors (p21, p16) as well as p53 and p27 expression. 
Ganetespib treatment led to an accumulation of p21 and p53, but not p16, in the nucleus of AC cells 
(Figure 3C–E). Correlating with this upregulation, increased p27 expression and the formation of SAHF 
was observed in ganetespib-treated cells (data not shown). Nuclear sizes were significantly increased in 
AC cells treated with 300 nM ganetespib for 48 h (Figure 3F). Extending the duration of treatment with 
lower concentrations of ganetespib also resulted in enlarged cell nuclei (Figure 3G), a result which would 
be consistent with ganetespib induction of premature senescence. 
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Figure 3. Ganetespib induces senescence in lung AC cells. Tumor cells were treated with 
ganetespib (0–300 nM) for 48 h and stained with primary antibodies against LC3 I/II, HMGB1, 
p21, p53 and F-actin (phalloidin). Each point presents the average intensities (pixels) estimated 
for 3000 cells. (A), (B). Analysis of autophagy associated proteins, LC3 I/II and HMGB1, in 
lung AC cells treated with ganetespib (0–300 nM). The total average fluorescence intensities 
of LC3 I/II (A) and HMGB1 (B) in cells are shown. (C)–(E). Ganetespib up regulates 
expressions of the senescence-associated markers (p16 and p21) in lung AC cells. (C). The 
representative images of T2821 and T2851 cells stained for p21 and for F-actin are shown. 
The average fluorescence intensities of nuclear p53 (D), and p21 (E) in the ganetespib-treated 
cells are presented. (F), (G). Ganetespib treatment leads to time-dependent and concentration-
dependent increase in the sizes of nuclei in AC cells. The average nuclear areas (pix) of cells 
treated with ganetespib for 2 days (F) and for 5 days (G) are shown. Cells were stained with 
Hoechst 33342, and analyzed by a Cellomics ArrayScan HCS Reader. 
Next, we analyzed for senescence-associated expression of β-galactosidase (SA-β-gal). As shown in 
Figure 4, the numbers of SA-β-gal-Positive cells in all cell lines were significantly higher when treated 
with 3 nM ganetespib than in the untreated control cultures. Furthermore as the ganetespib dosage was 
increased greater of numbers of SA-β-gal positive cells were detected. Overall, these data suggests that 
ganetespib produces its antitumor effect by multiple mechanisms in lung adenocarcinoma cells; 
including apoptosis, irreversible growth arrest and premature senescence. 
 
Figure 4. Senescence-associated β-galactosidase staining of ganetespib treated lung AC 
cells. Cells were treated with ganetespib (0–300 nM) for 3 days and senescence-associated 
β-galactosidase (SA-β-gal) staining was performed according to manufacturer instructions. 
Senescent cells were identified as cells stained blue. (A). Representative images (light 
microscope, 10 × magnification) of A549 cells that were stained for SA-β-gal after treatment 
with ganetespib (0, 30 nM), for 72 h are presented. (B)–(D). The numbers of SA-β-gal β-
positive cells and negative cells in cultures after the treatment with ganetespib (0, 3, 30 and 
300 nM) are shown. 
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2.4. Ganetespib Increases the Radiosensitivity of Lung Adenocarcinoma Cells in Vitro 
Western blot analysis showed that HSP90 was abundantly expressed in IR-treated cells (Figure 5A), 
raising the possibility that combining ganetespib with IR might increase the efficacy of antitumor 
therapies. A combined treatment regime utilizing ganetespib (0–300 nM) with cell irradiation (5 Gy) 
was tested for its effects on cell proliferation (Figure 5B,C). The combination of IR and 300 nM 
ganetespib dramatically reduced cell numbers at 48 and 72 h while the radiosensitizing effect of 30 nM 
ganetespib was only observed 72 h post-treatment. This combined treatment resulted in an increase in 
the number of cells undergoing mitotic catastrophe as well as cell death via apoptosis (data not shown). 
Low dose treatment of cells with ganetespib at 3 nM had no detectible effect (Figure 5B,C). Next the 
“classical” clonogenic survival assay was employed to test whether pretreatment with ganetespib and 
also post radiation treatment has similar radiosensitizing effects in NSCLC cells. Previously it was 
shown that the pretreatment of cells with HSP90 inhibitors led to radiosensitizing effect in different 
cancer cells [61–64]. 
 
Figure 5. HSP90 is expressed in IR-treated cells. HSP90 inhibitor ganetespib sensitizes cells to 
IR. (A) Western blots analysis of HSP90 expression in IR-treated AC cells. Cells were treated 
with IR, (0–7.5 Gy). At 72 h post-radiation, lysates were prepared and immunoblotted using 
antibodies against HSP90. GAPDH was included as a control. (B), (C) Ganetespib sensitizes 
lung AC cells to IR. The cells were treated with the combination of IR (5Gy) with ganetespib 
(0, 3, 30, 300 nM) and were stained with Hoechst33342 and counted at 48 h and 72 h  
post-radiation. Results are expressed as the mean ± SD of three independent experiments. 
Here we found that pretreatment of AC cells with ganetespib at low nanomolar concentrations  
(3 nM and 4 nM) for 24 h before IR treatment dramatically increased the radiosensitivity of AC cells  
(Figure 6A–C). Importantly, if ganetespib at the same low concentrations has been added into the culture 
media 24 h after IR, it also dramatically augment the antitumor effects of IR in decreasing the survival 
rate of IR-treated cells (Figure 6D–F and Table 1). A significant reduction in the proliferating fraction 
of T2821 and T2851 cells was shown following the treatment of cells with IR in combination with 
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ganetespib, 3 nM, (Figure 6A,C,D), with a dose enhancement ratio of 1.36 and 1.47, respectively (Table 1). 
Ganetespib (4 nM) also effectively sensitized A549 cells to IR (Figure 6A,B; Table 1). Taken together, 
this data demonstrates that both pretreatment with ganetespib and post radiation treatment with 
ganetespib has significant radiosensitizing effects in lung AC cells harboring diverse oncogenic 
mutations such as KRAS and EGFR. 
 
Figure 6. Pretreatment or post-radiation treatment of lung AC cells with ganetespib at a low 
concentration significantly reduces clonogenic survival. (A)–(C). Pretreatment AC with 
ganetespib radiosensitizes AC cells to IR. Cells were plated. The next day, ganetespib (3 nM 
or 4 nM) was added into the culture media for 24 h; then adherent cell cultures were 
irradiated (0–10 Gy). Cells were fixed and clonogenic survival was estimated on the seventh 
day after IR treatment. Radiation survival curves showing IR-sensitivity for cell lines, A549 
(A), T2821 (B) and T2851(C) that were pretreated with ganetespib (3 nM or 4 nM, green 
line) and without pretreatment (red line). (D)–(F). Post-radiation treatment of lung AC cells 
with ganetespib significantly reduces clonogenic survival. Cells were suspended, irradiated 
(0–10 Gy) and plated. The next day, ganetespib was added into the culture media. Cells were 
fixed and clonogenic survival was estimated on the seventh day after IR treatment. Radiation 
survival curves show IR-sensitivity of A549 (D), T2821 (E) and T2851 (F) cells grown 
without drug (red line), or grown in the presence of ganetespib (3 nM or 4 nM, green line). 
Average data of five experiments are shown. 
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Table 1. Comparison of radiosensitivity of NSCLC cells treated with HSP90 inhibitor 
ganetespib after irradiation. 
Cell Line T2821 T2851 A549 
Treatment IR IR + ganetespib, 3 nM IR IR + ganetespib, 3 nM IR IR + ganetespib, 4 nM 
D0 1.279 ± 0.12 * 1.047 ± 0.03 1.351 ± 0.07 * 1.28 ± 0.02 1.511 ± 0.07 * 1.358 ± 0.02 
ñ 5.314 ± 0.91 * 3.018 ± 0.26 4.901 ± 0.34 * 1.360 ± 0.34 3.830 ± 0.76 * 1.677 ± 0.15 
Results were calculated with linear quadratic and single hit multi-target models and presented as D0-Gy, (the dose required 
to reduce the fraction of survived cells to 37%) and ñ (extrapolation number derived by extension of the linear proportion 
of the IR survival curve to the ordinate of the graph using a log/linear plot). * p < 0.05 (compared to IR group). 
2.5. Ganetespib Inhibits Repair of IR-Induced DNA Damages in NSCLC Cells 
Next, we assessed the phosphorylated histone H2AX (γH2AX) foci, a sensitive indicator of DNA 
damage in the form of DNA double strand breaks (DSB). The γH2AX foci could be visualized as a 
bright spot that was present in all IR-treated cells (Figure 7A). No difference in γH2AX foci was 
observed at any time in AC cells exposed to either 3 or 30 nM ganetespib as a monotherapy  
(Figure 7B–D). However, treatment with 300 nM ganetespib did influence the formation of the  
γH2AX foci, suggesting that high concentration of drug could augment DNA damage. Ganetespib did 
not influence γH2AX foci formation at 0.2–1 h post-radiation. Six hour post-radiation, the numbers of 
γH2AX foci were reduced by approximately 1/3 of the level detected at 1 h, suggesting that by this time 
most DNA repair had already occurred. The differences between IR and IR treatment combined with 
ganetespib appeared 6–24 h post-radiation (Figure 7). Level of γH2AX foci significantly higher in cells 
treated with IR + ganetespib compared to cells treated with IR only (Figure 7). This delayed dispersal 
suggests that ganetespib inhibits the repair of DSBs induced by IR and increases radiosensitivity. 
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Figure 7. Effect of ganetespib on IR-induced γH2AX foci formation and foci duration.  
Cells were pretreated with ganetespib (0, 3, 30, 300 nM) for 2 h, irradiated (5 Gy) and 
cultured for 0–24. The cells were stained for γH2AX and with Hoechst 33342 and analyzed 
using HCA/HCS methods. (A). The representative images of control and irradiated cells 
stained for γH2AX foci are shown. (B)–(D). Ganetespib as monotherapy has a negligible 
effect on γH2AX formation. (E)–(G). Ganetespib at a low concentration of 3 nM influenced 
IR-induced γH2AX foci formation. Average numbers of the γH2AX foci per cell in AC cells 
treated with ganetespib in combination with IR, 5 Gy are shown at different time post-
radiation. (H). Combining IR with ganetespib at higher concentrations (30, 300 nM) inhibits 
DNA damage repair and γH2AX foci resolving. Average numbers of the γH2AX foci per cell 
are presented. Each point represents average data for 3000 cells. Data are expressed as the 
mean ± SD of three experiments. 
In light of these findings, we investigated the status of key DNA repair proteins—pATM (ataxia 
telangiectasia mutated), ATR (ataxia telangiectasia and Rad3-related), and 53-binding protein 1  
(53BP1) in lung AC cells treated with the combined treatment of IR plus ganetespib. As expected, IR 
upregulated pATM expression; with the highest degree of pATM upregulation found in T2851 cells 
where it co-localized with γH2AX and 53BP1 foci (Figure 8). Pretreatment of cells with ganetespib 
decreased pATM levels in IR-treated cells in all three cell lines (Figure 8B–D). 
 
Figure 8. Ganetespib downregulates ATM phosphorylation in IR-treated lung AC cells. 
A549, T2821 and T2851 cells were pretreated with ganetespib (0–300 nM) for 2 h, irradiated 
(5 Gy) and grown for 0–24 h before fixation. The cells were stained for pATM, 53BP1 and 
with Hoechst 33342. Cell images were analyzed using HCA/HCS methods. (A). Images of 
T2821 cells stained for pATM, and 53BP1 are shown. (B)–(E). Ganetespib affects pATM 
expression in irradiated cells. The total average fluorescence intensities of pATM in cells 
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were determined at 12 h post-radiation (B). Time-dependent and concentration dependent 
effect of ganetespib on the levels of pATM present in irradiated A549 (C), T2821 (D) and 
T2851 (E) cells are presented. Data are shown as % of the control. 
Furthermore, activation of both ATR and 53BP1 in irradiated AC cells was also affected by 
ganetespib treatment (Figure 9A,B). Taken together, these data suggest that treatment with nanomolar 
concentrations of ganetespib impacts multiple proteins involved in the DNA damage repair process. 
 
Figure 9. Ganetespib inhibits 53BP1, phospho-ATR and phospho-HSP90 nuclear proteins 
expression in IR-treated lung AC cells. Cells were pretreated with ganetespib (0–300 nM) 
for 2 h, irradiated (5 Gy) and grown for 12 h. The cells were stained for pATR (Ser473), 
53BP1, and pHSP90 (Th-7) and with Hoechst 33342. Cell images were analyzed using 
HCA/HCS methods. Ganetespib downregulated pATR (A), 53BP1 (B), and pHSP90 (C) 
proteins expression in IR-treated cells. The total average fluorescence intensities of proteins 
in control cells and cells treated with IR alone or in combination with increasing 
concentrations of ganetespib are shown. 
The direct involvement of HSP90 in the DNA damage response has been recently demonstrated [65]. 
It was found that the Thr-7 residue of HSP90 was phosphorylated immediately after DNA damage, and 
that pHSP90 accumulated at sites of DNA DSBs [65]. To determine whether HSP90 is directly involved 
in the DNA repair response in IR treated lung AC cells, the level of pHSP90 (Th-7) proteins present was 
assayed using the HCS and HCA methods. Irradiation of cells increased detected levels of pHSP90 proteins. 
The pHSP90 proteins were mainly located in the nuclei and co-localized with γH2AX foci in IR-treated lung 
AC cells. The lung AC cells which received the combined treatment showed a significant down regulation 
of pHSP90 proteins (Figure 9C). Interestingly, a difference was detected in the levels of protein expression 
(pHSP90, pATM, pATR and 53BP1) in the different cell lines. T2821 showed reduced protein 
Cancers 2015, 7 888 
 
 
expression as compared to the T2851 and A549 cells (Figures 8 and 9). Our data suggests that the 
combined ganetespib and IR treatment impacted several overlapping pathways involved in DNA repair 
and might lead to the formation of persistent DNA damage foci. 
2.6. Ganetespib at 3 nM Concentration Influences Cell Signaling Activity in Irradiated AC Cells 
PI3K/AKT signaling is activated in response to IR treatment in NSCLC cells [66].  
Ganetespib (10–1000 nM) has been shown to inhibit PI3K/AKT signaling in NSCLC cells [48–50,67]. 
Here we examined the modulation of PI3K/AKT signaling in irradiated A549, T2821 and T22851 
cells pretreated with ganetespib, 3 nM, using western blot (Figure 10). pAKT was highly expressed in 
untreated cells indicating the important role of PI3K/AKT signaling in primary T2821 and T2851 cells. 
Ganetespib, 3 nM, completely inhibited AKT phosphorylation in T2821 cells, and significantly 
suppressed the p-AKT level in T2851 cells; however ganetespib, 3 nM, have no effect in A549 cells 
(Figure 10). IR dramatically elevated the level of p-AKT in AC cells, however, post -radiation treatment 
with ganetespib significantly suppressed p-AKT levels in T2821 and T2851 cells and did not affect level 
of p-AKT in A549 cells (Figure 10). 
B
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IR, 5 Gy - - +        +      +        +
Ganetespib, 3nM             - +             - +       - +
Incubation, h                   24        24 6       6      24       24
T2821
RAD51
p AKT
P21
β-actin
T2851
A
RAD51
p AKT
P21
β-actin
RAD51
p AKT
P21
β-actin
A549
 
Figure 10. Ganetespib, 3 nM, inhibits IR-induced AKT phosphorylation, degrades the DNA 
repair protein RAD51 and induces p21 accumulation. A–C: A549, T2821 and T2851 cells 
were irradiated (0, 5 Gy), and incubated with ganetespib (0, 3 nM) for 6 or 24 h. Cell lysates 
were prepared and immunoblotted using antibodies against RAD51, pAKT, and p21. β-actin 
was included as a control. 
RAD51, a major protein involved in homologous recombination (HR), is involved in the repair of 
replication-induced DSBs and DSBs induced by IR [19,68,69]. RAD51 is missing in DNA-SCARs that 
are formatted in radiation-induced senescence cells [70], and the RAD51 expression in tumor cells might 
be affected by HSP90 inhibitors [71]. 
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To investigate these observations, we tested the effect of ganetespib, 3 nM, on RAD51 expression in 
irradiated lung AC cells (Figure 10). RAD51 was found to be abundantly expressed in naïve AC cells. 
In IR treated cells the RAD51 levels were found to be upregulated in only the T2821 cells.  
Following the post-radiation treatment of cells with ganetespib (3 nM) RAD51 protein were found to be 
degraded in T2821 and T2851 primary cell lines, but not affected in A549 cells (Figure 10). 
In contrast to RAD51, the CDK inhibitor p21 is present at very low levels in naïve AC cells and 
ganetespib, 3 nM, increased expression of p21 in AC cells (Figure 10). Notably, the combination of IR 
with ganetespib treatment dramatically upregulated the level of p21 in cells, suggesting that ganetespib 
might potentiate IR-initiated damage resulting in induced growth arrest and senescence. 
2.7. Combining Ganetespib with IR Increases Level of Persistent DNA Damages Triggering Senescence 
IR may cause unrepaired DSBs leading a persistent DNA damage response and to the generation of 
persistent foci and DNA-SCARS that functionally regulate multiple aspects of the senescent phenotype. 
DNA-SCARS lack RAD51 and require pATM, 53BP1 and γH2AX as important DNA-SCARS 
stabilizing components [70,72]. 
Here, we analyzed the effect of ganetespib at 5 days post-radiation on the expression of pATM, 
γH2AX (Figure 11), 53BP1 (Figure 12A–D) and SA-β-gal (Figure 12E) in AC cells. γH2AX and pATM 
proteins were found to be co-localized in persistent foci (Figure 11A). Only irradiated T2821 cells 
demonstrated an upregulation of pATM and γH2AX proteins; however, a dramatic upregulation of 
pATM and γH2AX was observed in all AC cell lines treated with the combined treatment of IR and 
ganetespib (Figure 11, shown for T2851 and T2821 cells). 
 
Figure 11. Combining IR with ganetespib increases the level of the persistent DNA damage 
foci while accumulating DDR mediators (pATM and γH2AX). T2821 and T2851 cells were 
irradiated (0, 5 Gy), and cultured in the presence of ganetespib (0–30 nM) for 5 days. The 
cells were stained for pATM (Ser1981), γH2AX and with Hoechst 33342 and were analyzed 
using HCA/HCS methods. (A), (B). Co-localization of pATM (red) and γH2AX (green) in 
persistent IR-induced foci. The representative images of T2821 cells (A) and T2851 cells 
(B), untreated cells and cells which were irradiated and grown with ganetespib (30 nM) for 
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5 days, are shown. (C)–(F). Ganetespib triggers the accumulation IR-induced persistent 
DNA damage foci. The total average fluorescence intensities of γH2AX and pATM in 
control cells and cells treated with IR alone or in combination with increasing concentrations 
of ganetespib were determined at 5 days post-radiation. 
Similarly, only T2821 cells showed an upregulation of 53BP1 expression after IR treatment (Figure 12), 
while 53BP1 protein expression was elevated in all AC cells treated with the combined treatment with 
IR and 30 nM ganetespib. T2821 cells which received the combination IR and a low dosage of 
ganetespib, 3 nM, also demonstrated upregulation of 53BP1 protein expression (Figure 12). These 
findings indicate that, depending upon the cellular context, ganetespib may enhance the formation of IR-
induced persistent DNA damage foci, and cellular senescence. 
 
Figure 12. Ganetespib upregulates the level of 53BP1 in IR-induced persistent DNA damage 
foci. A549, T2821 and T2851 cells were irradiated (0, 5 Gy), and cultured in the presence of 
ganetespib (0–30 nM) for 5 days. The cells were stained for 53BP1 and were analyzed using 
HCA/HCS methods. (A). The representative images of T2821 cells stained for 53BP1 are 
shown. (B)–(D). The total average fluorescence intensities of 53BP1, γH2AX and pATM in 
control cells and cells treated with IR alone or in combination with increasing concentrations 
of ganetespib were determined at 5 days post-radiation. (E). Senescence-associated  
β-galactosidase staining of AC cells treated with IR (5 Gy) and the combination of IR (5 Gy) 
with ganetespib (3 nM) at 5 days post-radiation. Representative images (light microscope, 
10× magnifications) of cells stained for SA-β-gal are shown. Senescent cells were identified 
as cells stained blue. *, significance of differences between ganetespib treated cells and 
nontreated cells at p < 0.05 
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2.8. Ganetespib Inhibits T2821 Xenografted Tumors Growths and Potentiates Effect of IR Treatment 
Finally, the antitumor effects of IR, ganetespib and the combination of IR with ganetespib treatments 
were assessed in a T2821 human lung AC xenograft model (Figure 13, Table 2). Our results show that 
all three treatments were tolerable for animals. Treatments of xenografted tumors with a single dose of 
IR (5 Gy), or with ganetespib applied as a monotherapy at a low concentration of 25 mg/kg twice a week, 
resulted in significant and similar levels of tumor growth reduction (Figure 13A). 
The statistical analysis of the individual tumor growth data revealed that by combining IR treatment 
with ganetespib resulted in a significant inhibition in tumor growth as compared to tumor growth in mice 
that received the IR only or ganetespib only treatments (Figure 13A, Table 2).  
 
Figure 13. Combined treatment IR with ganetespib effectively inhibits the growth of T2821 
tumors xenografted in mice. Mice bearing established T2821 tumors in the right hind limbs 
were pretreated with ganetespib and only the tumor region was irradiated with a single dose 
of 5 Gy. Ganetespib (25 mg/kg) was administered twice a week. Tumors were measured 
every 2-3 days, and tumor volumes were calculated. (A): Analysis of the tumor growth.  
(B and C): Xenografted tumor irradiation leads to dramatic upregulation of  
β-catenin expression in tumor tissues. The combination of IR and ganetespib mitigates the 
β-catenin upregulation in T2821 tumor tissue. *, significance of differences between groups 
of tumor tissues at p < 0.05. 
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Table 2. Comparison of T2821 tumors growth curves. 
Comparison 
p-value for the Comparison of 
Tumor Growth Slope Using  
F-test in the Mixed Model 
Adjusted p Value with the 
Bonferroni Correction 
IR vs. untreated 0.0062 0.0372 
Ganetespib vs. untreated <0.0001 <0.001 
IR + Ganetespib vs. untreated <0.0001 <0.001 
Ganetespib vs. IR 0.0814 0.4884  
IR + ganetespib vs. IR <0.0001 <0.001 
IR + ganetespib vs. ganetespib <0.0001 <0.001 
This finding demonstrates that the HSP90 inhibitor, ganetespib, significantly sensitizes T2821 lung AC 
cells to IR treatment in vivo. 
2.9. IR Treatment of The Tumors Upregulates β-catenin Expression; However, Combining IR with 
Ganetespib Suppresses β-catenin Level in T2821 Xenografted Tumors 
Wnt/β-catenin is involved in the regulation of stemness, EMT and metastasis in lung  
cancer [55,73,74]. To verify whether the radiosensitizing effect of ganetespib is associated with an 
alteration in β-catenin expression in lung tumors, we employed immunofluorescent staining for  
β-catenin in T2821 tumor tissue sections assessed by confocal microscopy (Figure 13B,C). Ganetespib 
exposure alone did not affect β-catenin expression in tumor tissues; whereas, IR-monotreatment of the 
tumors led to a dramatic upregulation of β-catenin expression in tumor tissues; however, by combining 
ganetespib treatment with IR significantly decreased the level of β-catenin in T2821 xenografts  
(Figure 13B,C). This result suggests that combining IR with HSP90 inhibition may mitigate the 
activation of WNT/beta-catenin signaling in IR treated cells. 
2.10. Discussion 
In this research, we have demonstrated for the first time that ganetespib treatment results in significant 
radiosensitization of lung AC cells in vitro and in vivo. Ganetespib has been shown to have this effect 
on AC cells of differing genetic backgrounds including KRAS mutant A549 cells, EGFR mutant primary 
T2851 cells, and primary T2821 cells that express wt KRAS and EGFR. Our data shows a strong 
cytotoxic effect for ganetespib as a mono-therapeutic in treatment of AC cells, and that ganetespib 
effectively sensitized AC cells to IR in combined treatments. Pretreatment of AC with ganetespib at low 
nanomolar concentrations (3 nM or 4 nM) for 24 h before gamma-irradiation dramatically increased the 
efficacy of IR treatment in vitro. These findings are in concordance with previous observations of the 
radiosensitizing effects of different HSP90 inhibitors in various cancer cells lines [61–64], our findings 
suggest that ganetespib is the most effective radiosensitizing SP90 inhibitor in lung AC cells. 
Of particular significance is our finding that post-radiation treatment of AC cells with ganetespib  
(3, 4 nM) also could potentiate antitumor effect of ionizing radiation, as we have shown using clonogenic 
survival assay in vitro. Further research is needed to elucidate the mechanisms of the observed post 
radiation activity of ganetespib. 
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Of even greater importance were our results for xenografted tumors grown in vivo and treated with 
ganetespib. In these experiments we found that ganetespib inhibited the T2821 xenografted tumors 
growth and potentiated the antitumor effect of IR. Our study suggests that the ganetespib 
radiosensitization effects are probably actuated through multiple mechanisms as the HSP90 protein has 
many protein clients. 
HSP90 inhibitors, as radiosensitizing agents, have significant promise because the molecular 
chaperone, HSP90, supports the many molecular pathways driving tumorigenesis along with IR therapy 
resistance [34,35,51]. The inhibition of HSP90 results in the degradation of its client proteins, leading 
to the concomitant disruption of multiple oncogenic signaling cascades through one molecular  
target [33,35,75]. Since the initial discovery of HSP90 as a target for anticancer therapy, incredible 
progress has been made in developing potent first- and second-generation HSP90 inhibitors.  
HSP90 inhibitors could sensitize a variety of tumor cell lines to IR [61–64]. However, there are no 
HSP90 inhibitors currently approved for cancer therapy [76]. 
Ganetespib, a new second-generation inhibitor of HSP90, showed activity in NSCLC both as 
monotherapy and in combination with docetaxel [35,47]. Our findings complement and extend those of 
the recent studies, showing that ganetespib as monotherapy exerts robust antitumor activity in different 
types of cancer [6,46,49,77,78]. 
In the previous studies, the most common responses of the cells to HSP90 inhibition were cell cycle 
arrest, which can occur through G1/M or G2/M transition arrest and it is likely dependent of CDK4, 
CDC2 and polo-like kinases [46,47,49,67,79]. We found that the treatment of lung AC cells with 
ganetespib alone, at low a nanomolar concentration, may lead to multiple antitumor effects such as: 
Inhibition of cells migration; cell proliferation and cell cycle progression leading to accumulation of 
cells in G2/M; activation of programmed cell death by apoptosis; and activation of the premature 
senescence. Ganetespib, as a single agent, inhibits the expression of antiapoptotic proteins (AKT and 
pAKT) in lung AC cells. This is the same for other cancer types [67,77,80–82], suggesting that 
ganetespib may translate well as a single agent for lung cancer treatment. 
Using γ-H2AX foci as a marker for DSB, we determined that ganetespib, at the concentrations of  
3 and 30 nM, did not induce DSBs while ganetespib at a higher concentration of 300 nM might induce 
DNA damages. Notably, the treatment of AC cells with ganetespib, at a low concentration of 3 nM, led 
to the degradation of RAD51 which is one of the major proteins involved in HR [19,68,69]. 
An important finding of this study was the capacity of ganetespib to induce permanent growth arrest 
and potentiate IR-induced senescence in lung AC cells. This is a new and significant feature of this drug 
because the stimulation of cellular senescence has been considered as a novel approach to improve 
cancer therapy with less severe effects than cytotoxic therapy [83]. Unlike apoptotic cells, which rapidly 
disintegrate, senescence cells remain viable for long intervals and are metabolically active, but are 
permanently in growth arrest. Several signaling cascades are associated with the establishment of 
senescence phenotype: Classical pathways such as p53 which activates p21; and p16 that prevents 
phosphorylation of the retinoblastoma protein (Rb) [70,84–86]. Another well-known senescent pathway 
is PTEN-p27. P27 protein (with inhibitory activity on CDK2-cyclinE) is frequently down regulated in 
many cancers and it’s expression is restored in senescence cells [87]. We showed that AC cells treated 
with ganetespib for 3–5 days display the key defining features of premature senescence cells: They are 
metabolically active, express markers of a senescence state such as p21, p53, and p27 and they are  
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SA-β-gal positive. T2821 and T2851 cells treated with ganetespib, at a nanomolar concentration for 24 
h, led to the degradation of the RAD51 DNA repair protein, downregulation of AKT and pAKT; 
upregulation of p21 and accumulation of persistent, non-reparable DNA damage foci. The p16-Rb 
pathway is not associated with senescence in AC cells treated with ganetespib, either with monotherapy 
or in combination with IR treatment. Other researchers have found similar results in their studies of another 
HSP90 inhibitor in nasopharyngeal carcinoma cells [88]. 
High migration and invasion capacities are key characteristics of metastatic tumor cells and lung 
cancer stem-like cells (CSCs) [28,89–91]. To date, drugs capable of blocking metastasis are not  
available [57]. Our findings that the HSP90 inhibitor ganetespib, at a nanomolar concentrations, 
effectively reduces the migration of AC cells, suggests an important anti-metastatic activity for 
ganetespib. Anti-migratory activity of other HSP90 inhibitors have also demonstrated that inhibition of 
HSP90 can function in blocking tumor cell migrations [92,93]. 
Now, it is generally accepted that the IR treatment of tumor cells in vitro may select for CSCs and 
induces EMT [28,94–97]; and the IR-resistance of these cells is associated with the activation of the 
Wnt/β-catenin signaling pathway in different cancers [98–100]. Here, using T2821 xenografted tumor 
tissue samples from our in vivo study, we have determined that a single fraction of IR leads to the 
significant upregulation of β-catenin expression in T2821 xenografted tumors. However, beta-catenin 
had no nuclear, but membrane or outside of nucleus localization. By combining IR with ganetespib 
treatment mitigates β-catenin upregulation, keeping concentrations of β-catenin similar to that seen in 
untreated tumors. This research is very promising and needs further investigation. 
Our observation that ganetespib in nanomolar concentrations dramatically inhibits the growth of lung 
tumor spheres in stem cell under selective conditions, suggests that ganetespib is able to abrogate 
radiation induced selection for lung CSCs and raises the possibility that the HSP90 inhibitor, ganetespib, 
is not only a potent radiosensitizing drug but also an antimetastatic agent. 
We determined that treatment with ganetespib induced radiosensitization in lung AC cells in vitro 
and in vivo. Our study suggests that ganetespib may impart radiosensitization through multiple 
mechanisms: (1) re-assortment of lung AC cancer cells into G2-M; (2) induction of apoptosis and mitotic 
catastrophe; (3) down regulation of the PI3K/Akt radioresistance pathway; (4) delay of DNA repair after 
IR treatment; and (5) accelerate IR-induced senescence. 
In response to IR induced DNA damages, cells typically activate ATM-CHK2 and ATR-CHK1 
signaling pathways to arrest the cell cycle and initiate DNA repair [21]. For these processes 
phosphorylation of H2AX (γ-H2AX) is necessary for the recruitment of many factors involved in DNA 
repair [101,102]. ATM, ATR, and DNA-PKcs are members of the phosphatidylinositol-3 kinase-like 
kinase (PIKK) family; and PIKKs are dependent on HSP90 for their activation via the R2TP complex 
and Tel2 [103]. HSP90 inhibition with ganetespib impacts multiple signaling cascades, including the 
activation of ATM, ATR and other PIKKs in IR-treated lung AC cells. This leads to the delay of DNA 
repair and to the accumulation of unrepaired, persistent γ-H2AX foci which has been discovered in 
senescence cells. Recent reports have shown the ability of HSP90 inhibitors to prolong the duration of 
γ-H2AX in irradiated prostate [64], breast, and cervical cancer cell lines [104]. However, we are the first 
to recognize the significant impact of HSP90 inhibition on the formation of the senescence phenotype 
in IR-treated lung AC cells. 
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Previous reports suggest that the HSP90 inhibitors radiosensitize the human prostate [105] and head 
and neck squamous cell carcinoma [106] cells by the abrogation of RAD51-mediated HR. Our data 
demonstrates the ganetespib-driven loss of RAD51, in both irradiated and non-irradiated cells, indicating 
that the radiosensitizing effect of ganetespib is likely associated not only with the degradation of RAD51 
but with the diminishing of multiple important DNA repair pathways and downregulation of important 
DNA repair proteins (such as ATM, ATR, 53BP1, etc.). Our data also shows an upregulation and nucleus 
localization of pHSP90 in irradiated AC cells, suggesting that HSP90 is directly involved in the DNA repair 
processes; nevertheless, this finding needs further investigation. In addition, our data suggests that the 
radiosensitizing effect of HSP90 inhibitors may arise from the broad down-regulatory effects (direct or 
indirect) of multiple critical radioresistance pathways, whose components are clients of the HSP90 [61,107]. 
An important finding of this study is the capacity of ganetespib to significantly improve the efficacy 
of radiation therapy in T2821 xenografts. Our data indicates a clear clinical relevance for combining 
ganetespib with radiation in the treatment of lung AC. 
3. Experimental Section 
3.1. Cells 
Human A549 cells were purchased from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). Cells were grown in culture media, as per ATCC recommendations, with supplemental 10% 
FBS (Atlanta Biologicals, GA, USA). Surgical lung adenocarcinoma samples were obtained from the 
University of Pittsburgh Cancer Institute (UPCI) Lung Specialized Program of Research Excellence 
(SPORE) with written consent from patients under an approved Institution Review Board protocol by 
University of Pittsburgh Scientific Review Committee (IRB# 01-09-27-07). Patient anonymous samples 
were used in the experiments according to protocol. We isolated T2821 and T2851 lung AC cells from 
surgical tumor samples (Table 3). To generate a stock of these cells, they were expanded in culture prior 
to harvesting and cryopreservation. While under investigation, T2821 and T2851 cells were grown in 
RPMI media supplemented with 10% FBS. 
Table 3. NSCLC sources for primary adenocarcinoma cell cultures. 
Tumor ID Tumor Stage Primary Tumor ? 
Mutations 
EML4/ALK 
KRAS BRAF EGFR 
T2821 IV( T4Nx) No. Second, T2N1 No No No No 
T2851 T2N0 Yes No No Yes, exon 21 No 
3.2. Reagents 
Hoechst 33342, anti-β-actin, anti-GAPDH, and anti-HMGB1 antibodies were purchased from  
Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). Draq5TM was purchased from eBioscience  
(San Diego, CA, USA). Antibodies against p16INK4a and pATM (Ser1981) were purchased from Abcam 
Inc. (Abcam, Cambridge, MA, USA). p21WAF1/Cip1A, ATM, AKT, pAKT (Ser 473), p ATR (Ser428) and 
β-catenin antibodies were purchased from Cell Signaling Technology Inc., (Danvers, MA, USA). 
Antibodies against 53BP1 and γH2AX (Ser139) were obtained from EMD Millipore (Darmstadt, 
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Germany). Rad51 and ATR antibodies were obtained from Santa Cruz Biotechnology, (Dallas, TX, 
USA). Antibodies against p53 and p62 were acquired from Novus Biologicals (Littleton, CO, USA). 
The phalloidin-FITC and secondary antibody conjugated with Alexa®-488, -546, and -680 were obtained 
from Molecular Probes (Invitrogen, Carlsbad, CA, USA). The HSP90 inhibitor ganetespib [3-(2,4-
dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one] was synthesized and 
kindly provided by Synta Pharmaceuticals Corp. (SYNTA Pharmaceuticals, Lexington, MA, USA). 
3.3. Irradiation 
AC cells were irradiated in vitro, as cell suspension or as monolayer, using the Shepherd Mark 168 
Irradiator, (137Cs Irradiator) (JL Shepherd, San Fernando, CA, USA) at a dose rate of 70.6 cGy per hour 
at room temperature. For our in vivo experiments, we used a Varian linear accelerator using 6 MeV 
photons with a dose rate of 300 monitor units/min (Varian Medical Systems, Inc., Palo Alto, CA, USA). 
The mice received a single dose of IR according to published methods [108]. The region of the right 
hind limbs of the mice (region that is bearing xenografted T2821 tumor cells) was irradiated with a single 
dose of 5 Gy. The animal body was shielded by a 10/2 mm value layer block so that only the right hind 
limb region was irradiated [108]. 
3.4. Cells Staining Procedure for Cellomics Array Scan Automated Imaging 
Cells were fluorescently stained as described [28,55]. Cells grown in 96-well plates and were fixed 
in 2% PFA for 20 min, permeabilazed with 0.1% Triton X-100 for 10 min, and incubated with primary 
antibodies for 1 h and with secondary antibodies for 1 h. Cell nuclei were then stained with Hoechst 
33342 at 2 μg/mL for 20 min to identify individual cells and to optimize focusing. All incubation and 
fixation procedures were performed at room temperature. Cell images were acquired using the Cellomics 
ArrayScan HCS Reader (Cellomics/ThermoFisher, Pittsburgh, PA, USA) and were analyzed using the 
Compartment or Target Activation BioApplication Software Modules. Data was captured, extracted and 
analyzed with ArrayScan II Data Acquisition and Data Viewer version 3.0 (Cellomics). 
3.5. Cell Proliferation and Viability Assays 
AC cells were seeded in triplicate in 96 well plates and incubated for 24–72 h in the absence or 
presence of different concentrations of ganetespib (0–200 nM). The number of viable cells was 
determined using 3-4,5-dimethyldiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) 
conversion assay, according to the manufacture’s protocol. In some experiments, cells were counted 
using the Cellomics ArrayScan HCS Reader after staining with 2 μg/mL of DNA binding dye, Hoechst 
33342, for 20 min. 
3.6. Tumor Sphere Growth 
Suspension growth of AC cells was assessed as described [28,55]. Single cell suspensions were 
prepared and plated at 100–500 cells/mL in ultra-low attachment 24 well plates (Corning, Corning, NY, 
USA) in MammoCult™, which is a serum-free liquid culture medium (Stem Cell Technologies, 
Vancouver, BC, Canada). Ganetespib (0–20 nM) was added into culture medium, and cells were 
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incubated for 10 days. The tumor sphere growth was analyzed under a phase-contrast microscope with 
10× objective and counted from at least three wells. 
3.7. In Vitro Clonogenic Assays 
To analyze effect of the pretreatment with ganetespib on clonogenic survival of irradiated cells, 
exponentially growing cells were harvested by exposure to trypsin and plated in 6 well plates, 500 cells 
per well. The next day, ganetespib (3 nM or 4 nM) was added into the culture media for 24 h; then 
adherent cell cultures were irradiated using a 137Cs gamma-ray (0–10 Gy). Cultures were incubated at 
37 °C in 5% CO2. Cells were fixed and stained with crystal violet; colonies ≥ 50 cells were counted and 
the size of the colonies were measured (Gel Count colony counter, Oxford Optronix, Oxford, UK) as we 
described [28]. 
To analyze effect of the post-radiation treatment with ganetespib, cell suspensions were prepared and 
irradiated with doses ranging from 0 to 10 Gy and plated in 6 well plates, 500 cells per well.  
Cultures were incubated at 37 °C in 5% CO2. The next day, HSP90 inhibitor ganetespib was added to 
the cultures at the final concentrations of 0–10 nM. At the seventh day after irradiation, cells were fixed 
stained with crystal violet; and counted as we described [28]. 
3.8. Immunofluorescence Detection of γH2AX, pATR, pATM, pHSP90 and 53BP1 
Cells growing in 96 well plates were pretreated with ganetespib (0, 3, 30, 300 nM) for 2 h, then the 
cells were irradiated 0–5 Gy at RT. After IR treatment, cells were incubated in the culture media 
supplemented with 10% of FBS, 37 °C, 5% CO2 for 0–30 h. Then the cells were fixed, permeabilazed 
and incubated with antibodies against γH2AX, 53BP1, p-ATR, p-ATM and p-HSP90 at room 
temperature for 1 h. 
3.9. Apoptosis Assay 
Apoptosis was analyzed by flow cytometry using Alexa Fluor 488-conjugated AnnexinV and 
propidium iodide (PI) (Molecular Probes, Eugene, OR, USA) as recommended by the manufactures.  
In this assay Cells were first treated with ganetespib (0, 3, 30, 300 nM) for 0, 6, 24 or 48 h then harvested, 
washed twice with ice cold PBS, resuspended in a 500 μL incubation buffer containing Annexin  
V-Alexa Fluor 488 and propidium iodide (PI), and incubated in the dark for 15 min. Analyses were 
performed using a Accuri C6 Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). 
3.10. Cell Cycle Analysis 
Cells growing in 6 well plates were exposed to the indicated concentrations of ganetespib (0,  
30 nM) for 48 h. Cells were then harvested and resuspended in ice cold PBS. Iced cold 70% ethanol was 
used to fix the cells and they were stored overnight at 4 °C, washed twice with PBS, and resuspended in 
50 μg/mL PI staining reagent containing 100 μg/mL RNase and 0.1% Triton X-100 for 30 min in the dark. 
Cells were analyzed by flow cytometry (Accury C6, Becton-Dickinson) and the percentage of cells in the 
different phases of the cell cycle was analyzed with Becton-Dickinson software. 
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3.11. Senescence and Autophagy Assays 
Senescence-associated β-galactosidase (SA-β-gal) activation was detected in ganetespib treated cells 
as described [109]. Cells growing in 24-well plates were treated with ganetespib for 0–5 days, and 
stained with X-Gal (Cell Signaling Inc., Senescence β-Galactosidase Staining Kit) according to the 
manufactures protocol. The senescent SA-β-gal + cells (stained blue) were determined by bright-field 
microscopy. Cells images were captured and numbers of senescent cells and unstained cells were 
counted in 5–10 fields in each well. Other senescence-associated markers, cyclin-dependent kinase 
inhibitors, p16INK4a, p21WAF1/Cip1, and p53, as well as autophagy associated markers, sequestosome-1 
(p62), light chain 3 (LC31/2) and High mobility group box 1 (HMGB1) were evaluated in  
ganetespib-treated cells using the Cellomics ArrayScan as described above. 
3.12. Monolayer Wound Healing Assay 
Cells were seeded into six-well plates at high density and were cultured for 2 days to produce monolayers. 
Confluent cell monolayers were then scratched using a plastic 10 µL-pipette tip as described [28]. 
Wounded monolayers were then washed four times with medium to remove cellular debris and incubated 
in culture medium supplemented with 10% FBS for 24 h. Images were captured at 0, 2, 4, 6 and 24 h 
post treatment using a ZEISS (light) microscope Axiovert 40C (Hamamatsu, Japan). Resulting wound 
diameters were measured. 
3.13. Western Blotting 
Western blotting analysis was performed as previously described [110]. The tumor cells were treated, 
and harvested at different time points. The harvested cells were disrupted using lysis buffer (Cell 
Signaling Technology, Danvers, MA, USA) in the presence of protease inhibitor and incubated on ice 
for 30 min (vortex every 10 min). Lysates were clarified by centrifugation and equal amounts of proteins 
resolved by SDS-PAGE before transfer to PVDF membrane (Bio Rad, Hercules, CA, USA).  
The membranes were blocked with 5% non-fat milk, incubated with primary antibodies followed by 
addition of secondary antibodies. Chemiluminescence signals were detected on the X-ray film.  
As an internal control the GAPDH or β-actin primary antibody was also probed. The gel-digiting 
software Un-Scan-It gel (Version 5.1; Silk Scientific, Inc., Orem, UT, USA) was used to quantify the 
intensities of Chemiluminescent bands detected. 
3.14. Tumor Xenografts 
Six- to eight-week-old female NOG-F mice, (Taconic Labs, Hudson, NY, USA) were housed 
according to IACUC protocols at the Hillman Cancer Center—University of Pittsburgh Cancer Institute. 
All protocols were approved by the IACUC of the University of Pittsburgh. Veterinary care was provided 
by the Division of Laboratory Animal Research of the University of Pittsburgh. To establish tumor 
xenografts, T2821 human adenocarcinoma cells were s.c. inoculated into the right hind limbs of NOG-
F mice (2 × 106 cells per mouse) as described [111]. Mice bearing established tumors (100–200 mm3) were 
randomized into treatment groups: (1) Control; (2) IR; (3) HSP90 inhibitor ganetespib; (4) IR + Hsp90 
inhibitor. The region of the right hind limb was irradiated with a single dose of 5 Gy according to 
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published methods [108]. Mice received an intra-peritoneal (i.p.) injection of either ganetespib (25 
mg/kg) formulated in 10/18 DRD [10% dimethyl sulfoxide (DMSO), 18% Cremophor RH 40, 3.6% 
dextrose, 68.4% water] or 10/18 DRD without ganetespid 48 h prior to IR treatment. Ganetespib (25 
mg/kg) treatments were continued twice a week for the duration of the experiment. Tumor volumes 
(mm3) were defined as follows: [(W1 × W1 × W2) × (π/6)], where W1 and W2 were the smallest and the 
largest tumor diameters (mm), respectively. Tumor growth inhibition was determined as described 
previously [112]. 
3.15. Tumor Analysis 
Tumor tissue samples from all treatment groups were embedded in OCT Compound (Miles), snap 
frozen, and stored at −80 °C. Cryostat sections (8 μm) were stained using hematoxilin and eosin and 
histopathologically evaluated. Three slides from each tumor were incubated with monoclonal anti-beta 
catenin antibody and cell nuclei were stained with Draq5TM. Slide images were acquired with Leica 
Laser Confocal Microscope, model DMRE TCS SL, and analyzed using ImageJ software. 
3.16. Statistics 
IR survival curves for in vitro treatment groups were analyzed by comparison with the  
linear-quadratic and the single-hit multi-target models. Statisical comparisons used the final slope of the 
survivorship curves, representing multiple-event killing (D0), and an extrapolation of the width of the 
shoulders on the radiation survival curve (ñ) [113]. Results for D0 and ñ were summarized as the  
mean ± the standard error (SEM) from multiple measurements and were compared using a two-sided, 
two-sample t-tests. In other in vitro experiments, comparisons between groups was done with the  
two-sided two-sample t-tests if the data was normally distributed; or Wilcoxon rank sum tests if not. 
One-way or two-way ANOVA were used for comparing multiple groups, followed by two sample  
t-tests for pair wise comparisons. For all these statistical analyses, a p-value of 0.05 was regarded  
as significant. 
Individual xenografted tumor growth curves were plotted by treatment group (untreated, IR, 
ganetespib, and IR + ganetespib). The tumor volume data were log-transformed, and a linear mixed 
model was built on the log-transformed volume data, where treatment, time of tumor measurement in 
days, and treatment by time interaction were used as fixed effects, and we assumed a random intercept 
and a random slope for each mouse. The Mixed procedure (i.e., Proc Mixed) in SAS (SAS Institute, 
Cary, NC, USA) was used to fit this model. The comparison of slopes between any two groups was 
performed in this model with an F-test, using Contrast statement in Proc Mixed. The p-values were 
adjusted with the Bonferroni correction for multiple comparisons. 
4. Conclusions 
Our study demonstrated that the HSP90 inhibitor, ganetespib, has robust antitumor activity as both a 
monotherapy in lung AC cells along with its significant effect in potentiation of ionizing radiation  
in vitro, in combined therapy with ionizing radiation. We determined that lung adenocarcinoma cells 
harboring diverse oncogenic mutations such as KRAS and EGFR were sensitized to ionizing radiation. 
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Ganetespib was also shown to: Inhibit cell growth and migration, tumor sphere formation induced 
apoptosis and cell cycle redistribution, led to irreversible cell growth arrest and the development of the 
senescence phenotype in lung adenocarcinoma cells. The most clinically significant finding of this study 
is our demonstration that treatment with ganetespib has the capacity to significantly improve the efficacy 
of IR therapy in primary human lung adenocarcinoma T2821 xenografts. 
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